Expression of genes encoding centrosomal proteins and the humoral response against these proteins in chronic myeloid leukemia

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F17%3A00011650" target="_blank" >RIV/00023736:_____/17:00011650 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11310/17:10333043

Výsledek na webu

<a href="http://dx.doi.org/10.3892/or.2016.5226" target="_blank" >http://dx.doi.org/10.3892/or.2016.5226</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3892/or.2016.5226" target="_blank" >10.3892/or.2016.5226</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Expression of genes encoding centrosomal proteins and the humoral response against these proteins in chronic myeloid leukemia

Popis výsledku v původním jazyce

In the present study, we showed that in comparison with healthy controls, the expression of four centrosomal genes (AURKA, HMMR, PLK1 and ESPL1) in the peripheral blood of CML patients was significantly enhanced at diagnosis and decreased to the basal level in most patients treated with imatinib mesylate for three months. In the remaining patients (17%), this decrease was delayed and was associated with worse overall survival. The detection of antibodies in sera showed that patients with higher overall antibody production had superior outcomes in terms of achieving major molecular response and failure-free survival. These data suggest that the dynamics of the response of centrosomal genes should be considered as a risk factor and immunity against centrosomal proteins may contribute to treatment response.

Název v anglickém jazyce

Expression of genes encoding centrosomal proteins and the humoral response against these proteins in chronic myeloid leukemia

Popis výsledku anglicky

In the present study, we showed that in comparison with healthy controls, the expression of four centrosomal genes (AURKA, HMMR, PLK1 and ESPL1) in the peripheral blood of CML patients was significantly enhanced at diagnosis and decreased to the basal level in most patients treated with imatinib mesylate for three months. In the remaining patients (17%), this decrease was delayed and was associated with worse overall survival. The detection of antibodies in sera showed that patients with higher overall antibody production had superior outcomes in terms of achieving major molecular response and failure-free survival. These data suggest that the dynamics of the response of centrosomal genes should be considered as a risk factor and immunity against centrosomal proteins may contribute to treatment response.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

<a href="/cs/project/NT13862" target="_blank" >NT13862: Využití centrozomálních proteinů pro prognostiku a vakcinoterapii chronické myeloidní leukemie</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Oncology reports

ISSN

1021-335X

e-ISSN

—

Svazek periodika

37

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

8

Strana od-do

547-554

Kód UT WoS článku

000390639800065

EID výsledku v databázi Scopus

2-s2.0-85006386932